Mandate

Vinge has advised SEB in connection with an issue of additional Tier 1 captial of MUSD 600

Vinge has advised Skandinaviska Enskilda Banken AB (publ) (“SEB”) as to Swedish law in connection with the bank’s issue of Additional Tier 1 Capital in the amount of MUSD 600 in the form of a debt instrument with no final maturity and with automatically conversion into Class A-shares if the CET1 ratio of the bank decreases to a certain level.

The instrument is listed on the Global Exchange Market regulated by the Irish Stock Exchange.

SEB issued the Additional Tier 1 Capital to refinance an old similar instrument that reaches its call date later this year and to optimize its capital structure.

Vinge’s team consisted mainly of Göran Nyström, Charlotte Levin, Albert Wållgren and Malte Hedlund.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025